InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: Protector post# 29735

Thursday, 05/27/2021 12:21:55 PM

Thursday, May 27, 2021 12:21:55 PM

Post# of 43207

How many doses does a patient need?
At what point in the disease development exactly does the administering 'optimally' need to be done. Earlier in the time-lines = more doses needed because they will be administered preventively to a larger number of people that in the end (with hindsight) wouldn't have needed them.


When they say 100k doses, they mean 100k treatments of 1,800mg. But I do think you have a point that things will change. Lenzilumab's trial has awesome efficacy on its first try. Efficacy will go even higher when they learn how to better administer it. I personally believe that they will eventually use lenzilumab on moderate and even mild patients. GM-CSF levels are elevated in the early stages. And the patients who have elevated GM-CSF early go on to be the patients who become severe and die. If they do start treating earlier stages, it might be a smaller dose that is given on a weekly basis until GM-CSF levels are lowered. Lenzilumab has the potential to be the SOC for milds, moderates, and severes.

This article explains GM-CSF's role in Covid:
https://www.bbc.com/news/health-56352128
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.